Gemcitabine With Curcumin for Pancreatic Cancer

Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00192842

Enrollment

Registered

2005-09-19

Start date

2004-07-31

Completion date

2010-09-30

Last updated

2010-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

carcinoma, pancreas, gemcitabine, curcumin

Brief summary

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Interventions

DRUGcurcumin (+ gemcitabine)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* locally advanced or metastatic adenocarcinoma of the pancreas * no prior chemotherapy * performance status 0-2 * adequate hematology and chemistry

Exclusion criteria

* serious concurrent medical condition

Design outcomes

Primary

Measure	Time frame
time to tumor progression	—

Secondary

Measure	Time frame
response rate	—
survival	—
clinical benefit	—
toxicity	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026